RD 42217Alternative Names: RD4-2217
Latest Information Update: 23 Apr 2003
At a glance
- Originator Rational Drug Design Laboratories
- Class Antiretrovirals
- Mechanism of Action RNA-directed DNA polymerase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported HIV-1 infections